ReviewPharmaceuticals (Basel, Switzerland)2024
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences.
Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- The mTOR/AMPK signaling axis in placental dysfunction and preeclampsia: mechanisms and therapeutic targeting with metformin.Molecular biology reports · 2026Review
- Impact of biguanide therapy on hepaticAnnals of nuclear medicine · 2026Article
- In Silico and In Vitro Evaluation of Bioactive Constituents Isolated fromBiomolecules · 2026Article
- Network Pharmacology and Zebrafish Model Elucidate the Hypoglycemic Mechanism of Major Compounds inFoods (Basel, Switzerland) · 2026Article
- Meta-Analysis of the Effect of Metformin on the Progression of Different Types of Prediabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Repurposing metformin for cardioprotection: mechanisms and therapeutic potential across cardiovascular pathologies.Frontiers in pharmacology · 2026Review
- Sex Differences in Albuminuria Risk with Metformin Use: Insights from a Cross-Sectional Study and Drug-Target Mendelian Randomization Analysis.Diabetes & metabolism journal · 2025Article
- From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin.International journal of molecular sciences · 2025Review
- Metformin as a Disease-Modifying Agent in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review of Preclinical and Clinical Evidence.Current issues in molecular biology · 2025Review
- Targeting Lipophagy in Liver Diseases: Impact on Oxidative Stress and Steatohepatitis.Antioxidants (Basel, Switzerland) · 2025Review
- Comparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus.Scientific reports · 2025Article
- The Antidiabetic Mechanisms of Cinnamon Extract: Insights from Network Pharmacology, Gut Microbiota, and Metabolites.Current issues in molecular biology · 2025Article
- The Role of Pharmacists in Identifying and Preventing Drug-Related Problems in PCOS Management.Pharmacy (Basel, Switzerland) · 2025Review
- Review
- Short-chain fatty acids as a novel intervention for high-fat diet-induced metabolic syndrome.Molecular and cellular biochemistry · 2025Article
- Article
- Drug repurposing for Alzheimer's disease and other neurodegenerative disorders.Nature communications · 2025Review
- Metformin as a disease-modifying therapy in osteoarthritis: bridging metabolism and joint health.Frontiers in pharmacology · 2025Article
- Future horizons in diabetes treatment: hypoglycemic activity of [1,2,4]triazino[2,3-Frontiers in endocrinology · 2025Article
- Modern Approaches to Diabetes: The Role of Phytochemicals in Targeting Molecular Receptors.Current topics in medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin is a synthetic biguanide used as an antidiabetic drug in type 2 diabetes mellitus, achieved by studying the bioactive metabolites of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.